23andMe Investor Presentation Deck

'610 Phase 1 Results: Dose Escalation Duration of Treatment Stable disease rate across ALL Phase 1 patients is 52% with median duration of 18.6 weeks Merkel cell carcinoma. Chordoma Poorly differentiated pancreatic neuroendocrine Colorectal Pancreatic adenocarcinoma Myoepithelial carcinoma Squamous cell carcinoma TUMOR TYPE Osteosarcoma Papillary carcinoma Well differentiated pancreatic neuroendocrine Clear cell chondrosarcoma Colorectal Squamous cell carcinoma. Esophageal adenocarcinoma Colorectal Melanoma Colorectal Esophageal adenocarcinoma Prostate Neuroendocrine Sarcoma Endometrial adenocarcinoma Sarcoma Ampullary adenocarcinoma Melanoma Colorectal Pancreatic adenocarcinoma 10 A Rasco, D, et al., 2023, SITC Annual Meeting #619 2 A 3 Best Overall Response OSD+PD 4 5 8 Time from 23ME-00610 First Dose (Months) 60 mg 200 mg 6 20 mg 7 9 A First PD or death Treatment ongoing X Last non-PD Assessment 10 600 mg 2 mg 6 mg Note: Treatment Duration=lend of treatment date first dose date + 1)/38.437. If a participant remained on treatment at the time of data cut-off, the data cutoff date was used. Colored portions of the horizontal bars represent the dose level the participants received. Intra-patient dose escalation to the next cleared dose level was permitted for participants who did not experience a Grade 3 or above study-drug related AE 1400 mg 11 Copyright © 2024 23andMe, Inc. 12 May 15, 2023 data cut-off date. 23andMe 25

View entire presentation